Bicycle Therapeutics Q4 net loss $49.1M; cash $526.4M; BT8009 Phase 2/3 trial recruiting

BICYCLE THERAPEUTICS PLC

2023-FY EPS reported -$5.08 revenue$26,976,000

Net loss $49.1M ($1.16/share) in Q4 2023 vs $30.0M prior year; full year loss $180.7M ($5.08).
Cash $526.4M as of Dec 31, 2023, up from $339.2M; financial runway expected into 2026.
BT8009 Phase 2/3 Duravelo-2 registrational trial for metastatic urothelial cancer now active and recruiting.
BT8009 showed 38% objective response rate in EV-naïve mUC patients; differentiated safety profile.
Stephen Sands appointed to Board; former chairman of Lazard's Global Healthcare Group, serves on Audit and Strategic Committees.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stephen Sands

Director

BCYC · BICYCLE THERAPEUTICS PLC

Effective: 2024-02-20
Filed: February 20, 2024, 6:59 PM ET

On February 20, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating & Corporate Governance Committee of the Board, appointed Stephen Sands to the Board, effective as of the close of business on February 20, 2024, New York City time.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BICYCLE THERAPEUTICS PLC reported financial results for the fiscal quarter and the year ended December 31, 2023.

Period: the fiscal quarter and the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 20, 2024, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2023 and other business highlights.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Sands was appointed as Director at BICYCLE THERAPEUTICS PLC.

Action: appointed
Role: Director

Exact text from the filing

On February 20, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating & Corporate Governance Committee of the Board, appointed Stephen Sands to the Board, effective as of the close of business on February 20, 2024, New York City time.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BICYCLE THERAPEUTICS PLC filing history →

Source: SEC EDGAR

accession 0001104659-24-025196

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.